Paxil CR on the upswing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's Paxil CR has recaptured 41% of its previous new prescriptions since its late June relaunch, the firm says July 28. "We're up to 2.2% new Rx share," Pharmaceuticals President David Stout told investors during GSK's second quarter earnings call. Paxil CR Q2 sales dropped 75% to $42 mil. Part of GSK's relaunch efforts include a 30-day free trial program (1Pharmaceutical Approvals Monthly July 2005, In Brief)...
You may also be interested in...
Paxil CR resumes shipments
GlaxoSmithKline resumes shipments of Paxil CR, four months after manufacturing problems led to FDA's seizure of the product at distribution and production facilities. Sales reps will offer 30-day free trial vouchers to support reintroduction. Resupply of Avandamet, which also was seized by FDA, is projected to begin by mid-July...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.